Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.

Scientific reports - 20 Jul 2017

Suelves Nuria, Kirkham-McCarthy Lucy, Lahue Robert S, Ginés Silvia

Abstract excerpt

Huntington's disease (HD) is a neurodegenerative disorder whose major symptoms include progressive motor and cognitive dysfunction. Cognitive decline is a critical quality of life concern for HD patients and families. The enzyme histone deacetylase 3 (HDAC3) appears to be important in HD pathology by negatively regulating genes involved in cognitive functions. Furthermore, HDAC3 has been implicated in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Corpus Striatum

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Huntingtin Protein

Share to Phenylenediamines

Share to Trinucleotide Repeat Expansion

Source

Open in PubMed Open full text

Identifiers

PMID: 28729730
DOI: 10.1038/s41598-017-05125-2
PMCID: PMC5519595

Genes

HDAC3
HTT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.PMID 28729730Read ↗

Selective inhibition of histone deacetylase 1 and 3 improves motor phenotype and alleviates transcriptional dysregulation in Huntington’s disease miceSemantic proximity Read ↗

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease MiceSemantic proximity Read ↗

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Semantic proximity Read ↗

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.Semantic proximity Read ↗

Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease miceSemantic proximity Read ↗

Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity.Semantic proximity Read ↗

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.Semantic proximity Read ↗

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.Semantic proximity Read ↗

HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.Semantic proximity Read ↗

HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological DisordersSemantic proximity Read ↗

Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?Semantic proximity Read ↗

Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.